Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lindy Biosciences’ Microglassification™ platform enables the formulation of highly concentrated protein suspensions suitable for subcutaneous injection. This allows patients to self-administer medications at home rather than requiring intravenous infusions in clinical settings. The company recently entered into a multi-target global licensing agreement with Novartis to apply this technology to transition select biologic drugs from IV infusion to convenient at-home injectables. No direct clinical results are reported as the company provides enabling technologies rather than developing its own therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lindy Biosciences.